| Generic Name | Mechanism of Action | 2009 FDA Approved Indication | Pharmacologically Similar Agents |
| abobotulinum toxin type A (botulinum toxin type A neurotoxin complex produced from a proprietary fermentation process) | acetylcholine release inhibitor | Treatment of cervical dystonia and cosmetic treatment of facial lines | onabotulinumtoxinA (botulinum toxin type A) |
| rimabotulinumtoxinB (botulinum toxin type B) |
| asenapine | serotonin, dopamine, alpha adrenergic, and histamine receptor antagonist | • Treatment of manic or mixed episodes associated with bipolar I disorder | clozapine, loxapine, olanzapine, quetiapine |
| • Acute treatment of schizophrenia |
| bepotastine | ophthalmic H1-receptor antagonist and inhibitor of the release of histamine from mast cells | Treatment of itching associated with allergic conjunctivitis | cromolyn, lodoxamine, nedocromil, pemirolast |
| besifloxacin | ophthalmic fluoroquinolone antibiotic | Treatment of bacterial conjunctivitis | ciprofloxacin, gatifloxacin, levofloxacin, ofloxacin, moxifloxacin |
| canakinumab | anti-human-IL-1β monoclonal antibody | Treatment of cryopyrin-associated periodic syndromes | anakinra, rilonacept |
| dexlansoprazole (R-enantiomer of lansoprazole) | (H+,K+)-ATPase inhibitor | • Management of erosive esophagitis | esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole |
| • Treatment of heartburn |
| dronedarone | potassium, calcium, and sodium channel blocker | Therapy of atrial fibrillation or flutter | amiodarone |
| everolimus | inhibitor of mTOR kinase activity | Treatment of advanced renal cell carcinoma | temsirolimus |
| febuxostat | xanthine oxidase inhibitor | Management of hyperuricemia | allopurinol |
| ferumoxytol (superpara-magnetic iron oxide coated in a carbohydrate shell) | hematopoietic | Treatment of iron deficiency anemia associated with chronic kidney disease | iron dextran, iron sucrose, sodium ferric gluconate complex |
| golimumab | tumor inhibitor necrosis factor α | Treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis | adalimumab, certolizumab, etanercept, infliximab, |
| iloperidone | dopamine, serotonin, and norepinephrine receptor antagonist | Treatment of schizophrenia | paliperidone, risperidone, ziprasidone |
| milnacipran | selective serotonin and norepinephrine reuptake inhibitor | Management of fibromyalgia | desvenlafaxine, duloxetine, venlafaxine |
| ofatumumab | monoclonal antibody against CD20 | Treatment of chronic lymphocytic leukemia | rituximab |
| pazopanib | multi-tyrosine kinase inhibitor | Treatment of advanced renal cell carcinoma | dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sunitinib |
| pitavastatin | HMG CoA reductase inhibitor | Management of hypercholesterolemia | atorvastatin, fluvastatin, pravastatin, rosuvastatin, simvastatin |
| pralatrexate | folate analogue metabolic inhibitor | Treatment of relapsed or refractory peripheral T-cell lymphoma | methotrexate, pemetrexed |
| prasugrel | platelet P2Y12 receptor antagonist | Management of acute coronary syndrome | clopidogrel, ticlopidine |
| romidepsin | histone deacetylase inhibitor | Treatment of cutaneous T-cell lymphoma | vorinostat |
| saxagliptin | dipeptidyl peptidase-4 inhibitor | Adjunct treatment for type 2 diabetes mellitus | sitagliptin |
| telavancin (semi-synthetic vancomycin derivative) | lipoglycopeptide antibacterial | Treatment of complicated skin and skin structure infections caused by susceptible isolates of gram-positive microorganisms | daptomycin, teicoplanin, vancomycin |
| tolvaptan | vasopressin V2-receptor antagonist | Treatment of hyponatremia | conivaptan |